In August 2017, based on the results of the evaluation of antitumor efficacy in syngeneic colon and ovarian carcinoma tumor models in MC38-S and ID8 mice, a clinical phase 1⁄2 trial was conducted for the OX40L-encoding mRNA-LNP treatment of 117 patients over the age of 18 years with a solid tumor or lymphoma. This evidence concerns the gene TNFSF4 and neoplasm.